Incidence and survival differences of differentiated thyroid cancer among younger women

References

• National Cancer Institute. Thyroid cancer treatment (PDQ®); cited Feb 2013. Available from: http://www.cancer.gov/cancertopics/pdq/treatment/thyroid/HealthProfessional/. Accessed October 4, 2013.
   Google Scholar
• American Cancer Society. Cancer facts and figures 2013. Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf. Accessed October 4, 2013.
   Google Scholar
• Waguespack S, Wells S, Ross J, Bleyer A. Chapter . 12: Thyroid cancer. In: National Cancer Institute. SEER AYA Monograph. Available from: http://www.seer.cancer.gov/publications/aya/12_thyroid.pdf. Accessed October 4, 2013.
   Google Scholar
• Kilfoy BA, Devesa SS, Ward MH, et al. Gender is an age-specific effect modifier for papillary cancers of the thyroid gland. Cancer Epidemiol Biomarkers Prev. 2009;18(4):1092–1100.
   Web of Science ®Google Scholar
• Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295(18):2164–2167.
   PubMed Web of Science ®Google Scholar
• Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer. 2009;115(16):3801–3807.
   PubMed Web of Science ®Google Scholar
• Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1973–2010), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2013, based on the November 2012 submission.
   Google Scholar
• Ying AK, Huh W, Bottomley S, Evans DB, Waguespack SG. Thyroid cancer in young adults. Semin Oncol. 2009;36(3):258–274.
   Web of Science ®Google Scholar
• McNally RJ, Blakey K, James PW, Gomez Pozo B, Basta NO, Hale J. Increasing incidence of thyroid cancer in Great Britain, 1976–2005: age-period-cohort analysis. Eur J Epidemiol. 2012;27(8):615–622.
   Web of Science ®Google Scholar
• Lise M, Franceschi S, Buzzoni C, et al. Changes in the incidence of thyroid cancer between 1991 and 2005 in Italy: a geographical analysis. Thyroid. 2012;22(1):27–34.
   Web of Science ®Google Scholar
• Sobrinho-Simoes M, Maximo V, Rocha AS, et al. Intragenic mutations in thyroid cancer. Endocrinol Metab Clin North Am. 2008;37(2): 333–362, viii.
   Web of Science ®Google Scholar
• Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol. 2008;21 Suppl 2:S37–S43.
   Google Scholar
• Alberti L, Carniti C, Miranda C, Roccato E, Pierotti MA. RET and NTRK1 proto-oncogenes in human diseases. J Cell Physiol. 2003;195(2):168–186.
   PubMed Web of Science ®Google Scholar
• Kebebew E. Hereditary non-medullary thyroid cancer. World J Surg. 2008;32(5):678–682.
   Web of Science ®Google Scholar
• Alsanea O, Wada N, Ain K, et al. Is familial non-medullary thyroid carcinoma more aggressive than sporadic thyroid cancer? A multicenter series. Surgery. 2000;128(6):1043–1050; discussion 1050–1051.
   Web of Science ®Google Scholar
• Malchoff CD, Malchoff DM. Familial nonmedullary thyroid carcinoma. Semin Surg Oncol. 1999;16(1):16–18.
   Google Scholar
• Bleyer A, Barr R, Hayes-Lattin B, Thomas D, Ellis C, Anderson B. The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer. 2008;8(4):288–298.
   PubMed Web of Science ®Google Scholar
• Vriens MR, Moses W, Weng J, et al. Clinical and molecular features of papillary thyroid cancer in adolescents and young adults. Cancer. 2011;117(2):259–267.
   PubMed Web of Science ®Google Scholar
• Kikuchi S, Perrier ND, Ituarte P, Siperstein AE, Duh QY, Clark OH. Latency period of thyroid neoplasia after radiation exposure. Ann Surg. 2004;239(4):536–543.
   Web of Science ®Google Scholar
• Horn-Ross PL, Canchola AJ, Ma H, Reynolds P, Bernstein L. Hormonal factors and the risk of papillary thyroid cancer in the California Teachers Study cohort. Cancer Epidemiol Biomarkers Prev. 2011;20(8):1751–1759.
   Web of Science ®Google Scholar
• Sakoda LC, Horn-Ross PL. Reproductive and menstrual history and papillary thyroid cancer risk: the San Francisco Bay Area thyroid cancer study. Cancer Epidemiol Biomarkers Prev. 2002;11(1):51–57.
   Web of Science ®Google Scholar
• Negri E, Dal Maso L, Ron E, et al. A pooled analysis of case-control studies of thyroid cancer. II. Menstrual and reproductive factors. Cancer Causes Control. 1999;10(2):143–155.
   Web of Science ®Google Scholar
• Zivaljevic V Vlajinac H, Jankovic R, et al. Case-control study of female thyroid cancer – menstrual, reproductive and hormonal factors. Eur J Cancer Prev. 2003;12(1):63–66.
   Web of Science ®Google Scholar
• De Remigis P, Raggiunti B, Nepa A, Giandonato S, Faraone G, Sensi S. Thyroid volume variation during the menstrual cycle in healthy subjects. Prog Clin Biol Res. 1990;341A:169–173.
   Google Scholar
• Schottenfeld D, Fraumeni JF. Cancer Epidemiology and Prevention. 3rd ed. Oxford: Oxford University Press; 2006.
   Google Scholar
• Dal Maso L, La Vecchia C, Franceschi S, et al. A pooled analysis of thyroid cancer studies. V. Anthropometric factors. Cancer Causes Control. 2000;11(2):137–144.
   PubMed Web of Science ®Google Scholar
• Dal Maso L, Bosetti C, La Vecchia C, Franceschi S. Risk factors for thyroid cancer: an epidemiological review focused on nutritional factors. Cancer Causes Control. 2009;20(1):75–86.
   PubMed Web of Science ®Google Scholar
• Iribarren C, Haselkorn T, Tekawa IS, Friedman GD. Cohort study of thyroid cancer in a San Francisco Bay area population. Int J Cancer. 2001;93(5):745–750.
   Web of Science ®Google Scholar
• Akslen LA, Nilssen S, Kvale G. Reproductive factors and risk of thyroid cancer. A prospective study of63,090 women from Norway. Br J Cancer. 1992;65:772–774.
   Web of Science ®Google Scholar
• Wong EY, Ray R, Gao DL, et al. Reproductive history, occupational exposures, and thyroid cancer risk among women textile workers in Shanghai, China. Int Arch Occup Environ Health. 2006;79(3):251–258.
   Web of Science ®Google Scholar
• Wingren G, Hatschek T, Axelson O. Determinants of papillary cancer of the thyroid. Am J Epidemiol. 1993;138(7):482^491.
   Web of Science ®Google Scholar
• Rossing MA, Remler R, Voigt LF, Wicklund KG, Daling JR. Recreational physical activity and risk of papillary thyroid cancer (United States). Cancer Causes Control. 2001;12(10):881–885.
   Web of Science ®Google Scholar
• Rahbari R, Zhang L, Kebebew E. Thyroid cancer gender disparity. Future Oncol. 2010;6(11):1771–1779.
   PubMed Web of Science ®Google Scholar
• Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973–1991. Cancer. 1997;79(3):564–573.
   PubMed Web of Science ®Google Scholar
• Welch Dinauer CA, Tuttle RM, Robie DK, et al. Clinical features associated with metastasis and recurrence of differentiated thyroid cancer in children, adolescents and young adults. Clin Endocrinol. 1998;49(5):619–628.
   Web of Science ®Google Scholar
• Brown RL, de Souza JA, Cohen EE. Thyroid cancer: burden of illness and management of disease. J Cancer. 2011;2:193–199.
   PubMed Web of Science ®Google Scholar
• Cooper DS, Doherty GM, Bryan RH, et al. Revised American thyroid association management guideline for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–1214.
   PubMed Web of Science ®Google Scholar
• Sosa JA, Udelsman R. Total thyroidectomy for differentiated thyroid cancer. J Surg Oncol. 2006;94(8):701–707.
   PubMed Web of Science ®Google Scholar
• White ML, Gauger PG, Doherty GM. Central lymph node dissection in differentiated thyroid cancer. World J Surg. 2007;5:895–904.
   Google Scholar
• Biondi B, Filetti S, Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab. 2005;1(1):32–40.
   Google Scholar
• Cooper, DS. TSH: suppressive therapy: An overview of long-term clinical consequences. Hormones. 2010;9(1):57–59.
   Google Scholar
• National Comprehensive Cancer Network. Thyroid carcinoma; cited Feb 2012. Available from: http://www.nccn.org/professionals/physician_gls/ PDF/thyroid.pdf. Accessed October 4, 2013.
   Google Scholar
• Ahmed M, Riddell A, Whittaker S, et al. Preliminary results of an open labeled phase 2 study evaluating the safety and efficacy of sorafenib in metastatic advanced thyroid cancer. J Clin Oncol. 2008;26:a6060.
   Web of Science ®Google Scholar
• Ravaud A, de la Fouchardière C, Courbon F, et al. Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial. J Clin Oncol. 2008;26(15S):6058.
   Google Scholar